Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth

In This Article:

Over the last 7 days, the United States market has risen by 2.3%, contributing to a 5.9% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment of steady growth, companies that combine robust earnings potential with significant insider ownership often stand out as promising opportunities for investors seeking alignment between management and shareholder interests.

Top 10 Growth Companies With High Insider Ownership In The United States

Name

Insider Ownership

Earnings Growth

Super Micro Computer (NasdaqGS:SMCI)

14.2%

29.8%

Hims & Hers Health (NYSE:HIMS)

13.2%

21.8%

Duolingo (NasdaqGS:DUOL)

14.4%

37.2%

Credo Technology Group Holding (NasdaqGS:CRDO)

12.2%

65.1%

Astera Labs (NasdaqGS:ALAB)

15.8%

61.4%

Red Cat Holdings (NasdaqCM:RCAT)

18.3%

123%

Niu Technologies (NasdaqGM:NIU)

36%

82.8%

Clene (NasdaqCM:CLNN)

19.4%

64%

Upstart Holdings (NasdaqGS:UPST)

12.6%

100.2%

Credit Acceptance (NasdaqGS:CACC)

14.4%

33.8%

Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Corcept Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Corcept Therapeutics Incorporated focuses on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of approximately $7.31 billion.

Operations: The company's revenue is primarily generated from the discovery, development, and commercialization of pharmaceutical products, totaling $675.04 million.

Insider Ownership: 11.7%

Earnings Growth Forecast: 39% p.a.

Corcept Therapeutics is experiencing strong growth, with earnings expected to increase significantly at 39% annually, outpacing the US market. Recent trials like ROSELLA and BELLA highlight its focus on relacorilant for treating serious conditions such as platinum-resistant ovarian cancer and hypercortisolism. The company's revenue is forecasted to grow at 24.8% per year, surpassing the market average. Despite high volatility in share price, Corcept trades well below estimated fair value, indicating potential undervaluation opportunities.

NasdaqCM:CORT Ownership Breakdown as at Apr 2025
NasdaqCM:CORT Ownership Breakdown as at Apr 2025

CoreWeave

Simply Wall St Growth Rating: ★★★★★★

Overview: CoreWeave, Inc. operates a cloud platform focused on scaling, support, and acceleration for GenAI with a market cap of $17.87 billion.